Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Avalo Therapeutics, Inc.
cerecor.comAI Executive Summary
AI-powered analysis of 8-K filing content
Avalo Therapeutics amended its merger agreement with AlmataBio to include a $15 million contingent payment milestone upon initiation of a Phase 3 clinical trial, reflecting progress in drug development and continued commitment to the strategic partnership.
Key Takeaways
Avalo entered into a Milestone Buyout Option Agreement amending the prior Merger Agreement dated March 27, 2024
Contingent consideration of $15 million is tied to the first patient being dosed in a Phase 3 trial
2 more takeaways
Related Filings (2)
2 more filings from Avalo Therapeutics, Inc. in the last 90 days